Boehringer Ingelheim invests €350m in Europe’s largest biotech development centre
pharmafile | April 28, 2023 | News story | Manufacturing and Production |
Boehringer Ingelheim (BI) have announced that it will invest €350m in a state-of-the-art Biologicals Development Centre (BDC) in Germany. It will join the company’s largest R&D and biopharmaceuticals site, which has more than 7,000 employees.
Biopharmaceuticals are highly complex drugs and one of the fastest growing sectors in the pharma industry, used as treatments for indications such as cancer, stroke and heart disease. 500 employees, including scientists from multiple disciplines and three different development units, will research and develop antibodies and therapeutic proteins. They will also have the capacity to produce developed substances from lab-scale to clinical trial supply.
Hubertus von Baumbach, chairman of the Board of Managing Directors, stated: “For many severe diseases with insufficient therapeutic options, highly complex biopharmaceutical molecules continue to give many patients great hope for treatment. In our new development centre, we will conduct cutting-edge research at the most advanced level to achieve therapeutic breakthroughs. This sets a benchmark for the industry and serves as an essential addition to our global biopharmaceutical R&D network.”
Winfried Kretschmann, minister-president of Baden-Württemberg, commented: “The new research and development centre of the family-owned company Boehringer Ingelheim in Biberach is a place where biological active substances of the next generation and beyond can be developed. They will be translated into products, new therapies and medicines that will noticeably improve the lives of many patients. I am pleased that one of the most successful, innovative and research-intensive pharmaceutical companies has a strong presence here in Baden-Württemberg. World-class research is taking place in Biberach. With their knowledge, skills and creativity, the employees make an important contribution to Baden-Württemberg as a location for research, innovation and healthcare.”
James Spargo
